Get to know our clinical trials

Trial of cemiplimab and chemotherapy in the perioperative treatment of patients with resectable non-small cell lung cancer.

THIS STUDY IS BEING CONDUCTED TO EVALUATE NEW TREATMENTS FOR LUNG CANCER PATIENTS SCHEDULED FOR SURGICAL REMOVAL.

Imagen del Dr. Miguel Fernández de Sanmamed Gutiérrez, Investigador principal del grupo Onco-Inmunología Aplicada y Traslacional de la Clínica Universidad de Navarra
Dr. Miguel Fernández de Sanmamed Gutiérrez Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • RANDOMIZED PHASE II PLATFORM STUDY TO EVALUATE THE ADMINISTRATION OF CEMIPLIMAB AND CHEMOTHERAPY VS. THE ADMINISTRATION OF CEMIPLIMAB PLUS OTHER ANTI-CANCER THERAPIES IN THE PERIOPERATIVE TREATMENT OF PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER.
  • Code EudraCT: 2023-503544-13-00
  • Protocol number: R2810-ONC-2268
  • Promoter: Regeneron Pharmaceuticals, Inc.
  • Molecule/Drug: cemiplimab

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION